BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 17982179)

  • 1. A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G.
    Stork R; Müller D; Kontermann RE
    Protein Eng Des Sel; 2007 Nov; 20(11):569-76. PubMed ID: 17982179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein.
    Hopp J; Hornig N; Zettlitz KA; Schwarz A; Fuss N; Müller D; Kontermann RE
    Protein Eng Des Sel; 2010 Nov; 23(11):827-34. PubMed ID: 20817756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin.
    Müller D; Karle A; Meissburger B; Höfig I; Stork R; Kontermann RE
    J Biol Chem; 2007 Apr; 282(17):12650-60. PubMed ID: 17347147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Half-life extension of a single-chain diabody by fusion to domain B of staphylococcal protein A.
    Unverdorben F; Färber-Schwarz A; Richter F; Hutt M; Kontermann RE
    Protein Eng Des Sel; 2012 Feb; 25(2):81-8. PubMed ID: 22238430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives.
    Stork R; Campigna E; Robert B; Müller D; Kontermann RE
    J Biol Chem; 2009 Sep; 284(38):25612-9. PubMed ID: 19628871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv.
    Korn T; Nettelbeck DM; Völkel T; Müller R; Kontermann RE
    J Gene Med; 2004 Jun; 6(6):642-51. PubMed ID: 15170735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
    Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins.
    Cantante C; Lourenço S; Morais M; Leandro J; Gano L; Silva N; Leandro P; Serrano M; Henriques AO; Andre A; Cunha-Santos C; Fontes C; Correia JDG; Aires-da-Silva F; Goncalves J
    J Biotechnol; 2017 Jul; 253():23-33. PubMed ID: 28549690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies.
    Stork R; Zettlitz KA; Müller D; Rether M; Hanisch FG; Kontermann RE
    J Biol Chem; 2008 Mar; 283(12):7804-12. PubMed ID: 18211902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preferential heterodimerization of a bispecific diabody based on a humanized anti-EGFR antibody 528.
    Asano R; Sone Y; Ikoma K; Hayashi H; Nakanishi T; Umetsu M; Katayose Y; Unno M; Kudo T; Kumagai I
    Protein Eng Des Sel; 2008 Oct; 21(10):597-603. PubMed ID: 18621782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of single-chain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T cell synapses.
    Stamova S; Feldmann A; Cartellieri M; Arndt C; Koristka S; Apel F; Wehner R; Schmitz M; Bornhäuser M; von Bonin M; Ehninger G; Bartsch H; Bachmann M
    Anal Biochem; 2012 Apr; 423(2):261-8. PubMed ID: 22274538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
    Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P
    J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo properties of a dimeric bispecific single-chain antibody IgG-fusion protein for depletion of CCR2+ target cells in mice.
    Schneider MA; Brühl H; Wechselberger A; Cihak J; Stangassinger M; Schlöndorff D; Mack M
    Eur J Immunol; 2005 Mar; 35(3):987-95. PubMed ID: 15719369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of the Fc fusion format to generate tag-free bi-specific diabodies.
    Asano R; Ikoma K; Kawaguchi H; Ishiyama Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    FEBS J; 2010 Jan; 277(2):477-87. PubMed ID: 20015073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-IL-2 fusion proteins: a novel strategy for immune protection.
    Penichet ML; Harvill ET; Morrison SL
    Hum Antibodies; 1997; 8(3):106-18. PubMed ID: 9322080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell killing of heterogenous tumor or viral targets with bispecific chimeric immune receptors.
    Patel SD; Moskalenko M; Tian T; Smith D; McGuinness R; Chen L; Winslow GA; Kashmiri S; Schlom J; Stanners CP; Finer MH; McArthur JG
    Cancer Gene Ther; 2000 Aug; 7(8):1127-34. PubMed ID: 10975673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineered protein scaffolds for molecular recognition.
    Skerra A
    J Mol Recognit; 2000; 13(4):167-87. PubMed ID: 10931555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogencity of HSA-L7/L12 (Brucella abortus ribosomal protein) in an animal model.
    Pakzad I; Rezaee A; Rasaee MJ; Tabbaraee B; Delpisheh A
    Iran J Immunol; 2009 Mar; 6(1):12-21. PubMed ID: 19293473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Fab-Selective Immunoglobulin-Binding Domain from Streptococcal Protein G with Improved Half-Life Extension Properties.
    Unverdorben F; Hutt M; Seifert O; Kontermann RE
    PLoS One; 2015; 10(10):e0139838. PubMed ID: 26430884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.
    Kellner C; Bruenke J; Stieglmaier J; Schwemmlein M; Schwenkert M; Singer H; Mentz K; Peipp M; Lang P; Oduncu F; Stockmeyer B; Fey GH
    J Immunother; 2008; 31(9):871-84. PubMed ID: 18833000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.